GH1 and Prader-Willi syndrome: GH therapy has been approved by the US Food and Drug Administration (FDA) for patients with GH deficiency (GHD, 1985), chronic renal insufficiency (1993), Turner syndrome (TS, 1997), or Prader-Willi syndrome (PWS, 2000), for children with a history of intrauterine growth restriction (IUGR) [small for gestational age (SGA), 2001], short stature with homeobox-containing gene deficiency (2006), or Noonan syndrome (NS, 2007) [4–6].